

Questions to Ask About Participating in a Clinical Trial	Myeloma Clinical Trial Resources
<ul style="list-style-type: none"> ▪ How can this treatment help me? ▪ What are potential side effects? ▪ Have you treated other patients with this therapy? ▪ What are the risks compared to the standard of care? ▪ What is the commitment from me? 	<p>ClinicalTrials.gov Myeloma Crowd myelomacrowd.org The Leukemia & Lymphoma Society LLS.org SparkCures sparkcures.com</p>

Clinical Trial Phases

Phase I: The goal is to test the safety of the drug, finding the appropriate dose that produces the fewest side effects.

Phase II: Further assesses the safety of the drug and the effectiveness of the treatment.

Phase III: Compares the efficacy of the new treatment to the standard-of-care treatment.

Phase IV: Study that looks at drugs that have already been approved to get additional safety information and to learn more about long-term benefits and side effects.

Glossary Terms

Aspirate: Withdrawing fluid, tissue, or other substance from the body for further examination of a disease or condition.

Bone Marrow Biopsy: A procedure that involves collecting a small sample of bone marrow, usually from the hip bone, in order to be examined by a laboratory. This procedure is used to confirm an MPN diagnosis and may be used to monitor the disease over time.

CAR (Chimeric Antigen Receptor) T-Cell Therapy: Treatment in which the T cells (a type of immune system cell) of a patient are laboratory-altered to attack cancer cells in the body.

Informed Consent: Provides a thorough explanation of the purpose of the research, including the role of the patient and how the trial will work.



M-Protein (M-Spike): Abnormal protein secreted by plasma cells that usually indicate disease when found in the blood or urine.

MRD (minimal residual disease): Measurement of the number of myeloma cells found in the bone marrow of patients in remission after a clinical response to treatment. MRD is relevant as the residual myeloma cells may indicate progression or relapse.

Standard of Care: An established guideline that is consensus among experts as the most appropriate and/or effective treatment for a specific type and stage of cancer.

Clinical Trials 201 | Myeloma

Clinical Trials 201 | Myeloma is brought to you by the Patient Empowerment Network. It is made possible through support from Janssen Oncology, Inc. and generous donations from people like you.

 question@powerfulpatients.org	www.powerfulpatients.org	 @power4patients
--	--	--